Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2–Positive Breast Cancer: Analysis of the NSABP B-31 Trial

IMPORTANCE: Preclinical models and studies in the metastatic and neoadjuvant settings suggest that single nucleotide polymorphisms in FCGR3A and FCGR2A may be associated with differential response to trastuzumab in the treatment of ERBB2/HER2–positive breast cancer, by modulating antibody-dependent...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Oncol
Main Authors: Gavin, Patrick G., Song, Nan, Kim, S. Rim, Lipchik, Corey, Johnson, Nicole L., Bandos, Hanna, Finnigan, Melanie, Rastogi, Priya, Fehrenbacher, Louis, Mamounas, Eleftherios P., Swain, Sandra M., Wickerham, D. Lawrence, Geyer, Charles E., Jeong, Jong-Hyeon, Costantino, Joseph P., Wolmark, Norman, Paik, Soonmyung, Pogue-Geile, Kay L.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5344747/
https://ncbi.nlm.nih.gov/pubmed/27812689
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2016.4884
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados